Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Medical Xyrem NDA Filing Planned For Fourth Quarter 2000

Executive Summary

Orphan Medical will submit an NDA for the gamma hydroxybutyrate product Xyrem for the treatment of narcolepsy-associated cataplexy by early fourth quarter 2000.

You may also be interested in...



Orphan Medical Xyrem

Sodium oxybate for treatment of narcolepsy and reduction of cataplexy will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 15. Risk management will be the main focus of the committee's deliberations, FDA said. The NDA, filed Oct. 10, 2000, has received priority review status (1"The Pink Sheet" Nov. 29, 1999, p. 11)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS035243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel